Welcome to our dedicated page for PMGC Holdings news (Ticker: elab), a resource for investors and traders seeking the latest updates and insights on PMGC Holdings stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect PMGC Holdings's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of PMGC Holdings's position in the market.
AGA Precision Systems (NASDAQ: ELAB) executed a Long-Term Agreement (LTA) with Turbo-Jet Products on March 31, 2026 to supply mission-critical aerospace and defense components.
The LTA establishes a five-year initial term with annual renewal provisions and governs future purchase orders, supporting regulated U.S. government and defense-related programs. AGA cites its AS9100 certification and ITAR compliance as enablers for quality, traceability, and regulatory adherence.
PMGC Holdings (NASDAQ: ELAB) filed its Form 10-K for fiscal year ended December 31, 2025, reporting a year of capital deployment and asset growth. Total assets rose 43% to approximately $12.87M and shareholders' equity increased to about $7.84M.
The company completed three acquisitions in 2025 (Pacific Sun Packaging on July 7, AGA Precision Systems on July 18, and Indarg Engineering on Oct 26) to expand precision manufacturing and specialty IT packaging operations, and advanced biopharma subsidiary Northstrive with clinical and preclinical programs targeting muscle preservation alongside GLP-1 therapies.
NorthStrive Biosciences (NASDAQ: ELAB) announced a third amendment to its License Agreement with MOA Life Plus (KOSDAQ: 142760) covering dual myostatin assets EL-32 and EL-22.
The Amendment updates the timing and key development milestones for human clinical programs, aligning schedules with both parties' R&D and regulatory expectations and reinforcing disciplined development planning for the human health portfolio.
PMGC (NASDAQ: PMGC) announced that its wholly owned subsidiary SVM Machining completed ITAR registration on March 24, 2026 and is in compliance with U.S. export‑control rules.
The company said the registration enables SVM to pursue defense and aerospace programs, increases eligibility as a qualified supplier to Tier 1 defense contractors and supports PMGC's strategy to expand into high‑value, defense‑related manufacturing.
PMGC Holdings (Nasdaq: ELAB) subsidiary NorthStrive Biosciences initiated a preclinical study of EL-32 to evaluate preservation of lean muscle while promoting fat loss, alone and combined with GLP-1 therapy semaglutide. The DIO mouse study will assess body weight, fat mass, lean mass, glycemic markers, and composition, with dosing, analysis, and CRO reporting planned over the coming months to inform potential follow-on studies.
PMGC Holdings (NASDAQ: ELAB) will effect a 1-for-6 reverse stock split of its common stock, effective 12:00 AM ET on March 10, 2026. Each six shares will consolidate into one, fractional holders will receive whole shares, and the CUSIP will change to 73017P508.
The company expects ~3,248,764 shares outstanding before the Split and ~541,461 shares outstanding immediately after, with outstanding awards, options and warrants adjusted proportionally.
NorthStrive Biosciences (Nasdaq: ELAB) filed ten U.S. patent applications on Feb. 19, 2026, extending its EL-22 and EL-32 technologies into animal health and agricultural markets.
The filings cover muscle growth and yield in livestock and poultry, aquaculture growth and emissions reduction, and list ten U.S. application numbers for EL-22 and EL-32.
NorthStrive Biosciences (NASDAQ: ELAB) executed a definitive, exclusive license agreement with Modulant Biosciences for its EL-22 and EL-32 myostatin-engineered probiotic programs for non-human animal health (worldwide excluding the Republic of Korea).
The License grants Modulant exclusive, royalty-bearing, sublicensable rights to develop, manufacture, and commercialize products from issued patents, pending applications, and know-how; Modulant assumes development, regulatory, manufacturing, and commercialization responsibilities while the agreement excludes any human pharmaceutical applications.
NorthStrive Biosciences (NASDAQ:ELAB) updated the Phase III timeline for its AI development program with strategic partner Yuva Biosciences. Phase III was initiated on December 17, 2025 and initially expected to last ~6–9 weeks. Upgraded sixth‑generation classifier models improve screening accuracy, and Yuva now expects Phase III results in Q2 2026. NorthStrive notes it does not control Yuva’s timeline and results remain subject to change.
PMGC Holdings (NASDAQ: ELAB) completed the acquisition of SVM Machining, a Northern California ISO 9001:2015 certified CNC precision machining firm. PMGC purchased 100% of SVM on a cash-free, debt-free basis for a $2.25M base price with a $250,000 indemnification holdback and earnout potential. SVM reported $3,042,701 revenue for the fiscal year ended December 31, 2024. The deal expands PMGC’s multi-site precision manufacturing platform across aerospace, defense, medical, semiconductor, biotech, and transportation markets.